Eterna Therapeutics Inc (ERNA) Stock Price, Quote & News

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. Th...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 798 6700

Website: www.ernexatx.com

Address:

1035 Cambridge Street, Suite 18A, Cambridge, United States

StreakGeek Jul. 2 at 5:23 PM

$DKI $ASBP $VEEE $ERNA identity

0 · Reply

TopSarge Jun. 29 at 7:58 PM

$ERNA could go soon

0 · Reply

topstockalerts Jun. 25 at 8:45 PM

$ERNA this stock is slowly forcing its way onto the radar.

0 · Reply

q1788 Jun. 25 at 4:50 PM

$ERNA $$$$

0 · Reply

Gemola Jun. 25 at 4:20 PM

$ERNA Loaded ...mis at your own peril.

0 · Reply

Medullo Jun. 25 at 4:13 PM

$ERNA Another runner on no news, that's the 5th one in the last hour.

0 · Reply

Ernexatx Jun. 25 at 1:39 PM

$ERNA Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients Watch the video here: https://vimeo.com/1203972399/7f3bed7bb1 Press Release: https://www.ernexatx.com/press-releases/ernexa-therapeutics-positioned-to-become-a-clinical-stage-biotechnology-company-as-erna-101-on-track-for-planned-q3-2026-ind-submission-and-first-in-human-study

0 · Reply

focafoca99 Jun. 25 at 1:32 PM

$ERNA provides a new CEO Corner platform to give shareholders deeper insight into its cell-therapy strategy and progress.

0 · Reply

Red2Profit Jun. 19 at 1:51 PM

$ERNA Could we see a big move soon? Break 8.32 and let's see if we can get 15+. A good catalyst would help.

1 · Reply

Ernexatx Jun. 17 at 1:13 PM

$ERNA Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study https://www.globenewswire.com/news-release/2026/06/17/3313445/0/en/ernexa-therapeutics-positioned-to-become-a-clinical-stage-biotechnology-company-as-erna-101-on-track-for-planned-q3-2026-ind-submission-and-first-in-human-study.html

0 · Reply